Mindset Pharma Inc has announced that preclinical proof-of-concept data comparing its clinical candidate, MSP-4018, against 5-MeO-DMT further demonstrate strong efficacy and an improved safety profile as a next-generation psychedelic medicine.
Mindset, a drug discovery and development company focused on creating next-generation psychedelic medicines to treat neurological and psychiatric disorders, said due to the strong preclinical efficacy and safety data in support of MSP-4018, combined with its expedited manufacturing process, it believes its Family 4 clinical candidate has the potential to provide a safer and more scalable therapeutic alternative to its first-generation 5-MeO-DMT.
“We believe this preclinical data will enable us to quickly advance this novel compound into human clinical trials,” CEO James Lanthier said in a statement.
READ: Mindset Pharma further validates lead candidate MSP-1014 as a next generation psilocybin analog through drug discrimination assay
Mindset’s Family 4 compounds are DMT and 5-MeO-DMT-inspired novel drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings. The company has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.
“The latest preclinical proof-of-concept data showed that, in addition to its strong efficacy, both locomotor activity and rearing behavior for MSP-4018 did not decline at a range of doses tested, compared to the profound decline observed in 5-MeO-DMT, indicating a remarkably improved safety profile for MSP-4018,” chief scientific officer Joseph Araujo said.
“In addition, we saw further evidence of psychedelic activity, reflected in the head twitch response of mice,” he added.
Contact the author at stephen.gunnion@proactiveinvestors.com